Outcomes of treatment with cyclic administration of dienogest after ovarian endometriotic cystectomy.
To evaluate the outcomes of patients treated with cyclic administration of dienogest after ovarian endometriotic cystectomy, following the completion of treatment. We retrospectively evaluated 26 patients treated with dienogest (2 mg/day) after cystectomy (revised American Society for Reproductive Medicine [r-ASRM] stage III-IV) in a pilot study. Dienogest was administered cyclically, for a total of six cycles, each comprising three weeks on and one week off. Outcomes of interest included severity of menstrual pain and recurrence of cysts at baseline, during the immediate post-treatment period and at the final outpatient follow-up. The mean outpatient follow-up period was 45.0 months. The visual analog scale score for menstrual pain following 6 cycles of dienogest treatment was significantly lower than that at baseline; it remained low at the final follow-up. The recurrence rates of cysts were 4% and 21% at 24 and 48 months after the completion of dienogest treatment, respectively. Six patients with recurrent disease were all classified as having r-ASRM stage IV. Our results suggest that cyclic dienogest for six months after cystectomy could relieve menstrual pain and reduce the recurrence of cysts, for approximately four years. The necessary treatment period for patients with r-ASRM stage IV disease requires further study.
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Toru
T
Yanase
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Manako
M
Ishida
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Shota
S
Nishijima
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Kyoko
K
Morikawa
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Tomokazu
T
Yokoo
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Yoshihiro
Y
Takaki
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Ikunosuke
I
Tsuneki
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Masaki
M
Tamura
a Department of Obstetrics and Gynecology , Niigata City General Hospital , Niigata , Japan.
Takumi
T
Kurabayashi
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010535:Laparoscopy; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010048:Ovarian Cysts / Q000601:surgery*; D017699:Pelvic Pain / Q000517:prevention & control*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D018931:Antineoplastic Agents, Hormonal; C023635:dienogest; D009277:Nandrolone
Cyclical administration; dienogest; endometriosis; outcome; pregnancy; recurrence